By Pierre Bertrand

 

Sanofi said a second phase three trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy.

Sanofi said that its Notus trial confirmed positive published results from the Phase 3 Boreas trial.

The Notus trial found that the treatment "significantly reduced exacerbations" and that treatment with Dupixent led to rapid and significant improvements in lung function for patients with the life-threatening respiratory disease, COPD.

"These results were from an interim analysis and, given the overwhelming positive efficacy of the primary endpoint, will be considered the primary analysis of the trial," Sanofi said.

It added that it and Regeneron plan to submit these latest findings, in addition to the data from the Boreas trial, to the U.S. Food and Drug Administration by the end of the year.

 

Write to Pierre Bertrand at pierre.bertrand@wsj.com

 

(END) Dow Jones Newswires

November 27, 2023 02:25 ET (07:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Sanofi